Liver disease resulting from chronic HCV infection is a major cause of morbidity and mortality among HIVinfected patients in the developed world [1] . HCV therapy with 48 weeks of combination pegylated interferon (PEG-IFN) plus ribavirin is the current standard intervention that can cure chronic HCV [2] [3] [4] and reduce the risk of liver-related complications [5] [6] [7] [8] . Although a number of factors have been shown to affect virological response to HCV therapy among coinfected patientsnotably HCV genotype, baseline HCV viral load, dosage of antiviral therapy and adherence [2-4,9,10] -the effect of antiretroviral medications on early and sustained virological response remains unknown.
Introduction
analogue abacavir [11] [12] [13] [14] ; abacavir has been hypothesized to compete intracellularly with ribavirin, another guanosine analogue, for enzymes involved in ribavirin phosphorylation and could therefore interfere with the antiviral effect of this drug [14] . However, these studies included only European patients, included few patients on abacavir, often did not restrict analyses to patients receiving antiretroviral therapy (ART) and reported conflicting results. As a result, it remains unclear if abacavir is associated with reduced HCV virological response. Furthermore, the effect of other antiretroviral medications on HCV treatment response has not been well evaluated [15] . As antiretroviral agents could affect the chances of achieving virological response to combination HCV therapy in coinfected patients, the results of such studies can help inform decisions about medication choices in this population.
To address this issue, we determined if the use of abacavir was associated with reduced early and sustained virological response among antiretroviral-treated HIV/HCV-coinfected patients who received PEG-IFN plus ribavirin in clinical practice. In secondary analyses, we examined whether other antiretroviral medications reduced HCV treatment response.
Methods

Study design and patients
A retrospective cohort study was conducted among antiretroviral-treated HIV/HCV-coinfected patients initiating HCV therapy with PEG-IFN-α2a or -α2b plus ribavirin between 1 January 2001 and 30 June 2008 at six coinfection clinics: Penn Presbyterian Medical Center, Philadelphia, PA, USA; Philadelphia Veterans Affairs (VA) Medical Center, Philadelphia, PA, USA; Jonathan Lax Treatment Center, Philadelphia, PA, USA; Hahnemann Hospital, Philadelphia, PA, USA; St. Michael's Hospital, Newark, NJ, USA; and Lehigh Valley Hospital, Allentown, PA, USA. Patients were eligible for inclusion if they met four criteria: they had detectable HCV RNA levels prior to HCV therapy, received an initial course of PEG-IFN plus ribavirin, had evidence of HIV infection and were receiving ART (defined as three antiretroviral medications from at least two different drug classes [16] ) at the start of HCV therapy. Patients who were treated with PEG-IFN monotherapy or who did not receive ART were excluded.
Potentially eligible patients were identified by reviewing lists of coinfected patients who received PEG-IFN plus ribavirin at the sites during the observation period. All eligible patients were included. The study was approved by the Institutional Review Boards of the University of Pennsylvania, Philadelphia VA Medical Center, Jonathan Lax Treatment Center, Drexel University, St. Michael's Hospital and Lehigh Valley Hospital.
Main study outcomes
The main study outcome was early virological response, defined as a decrease in HCV RNA of ≥2 log IU/ml at 12 weeks of HCV therapy [17] [18] [19] . Patients who prematurely withdrew from HCV therapy before 12 weeks of treatment were considered not to have had early virological response.
Secondary outcomes included: change from baseline of HCV viral load at 12 weeks of HCV therapy; endof-treatment response, defined as a negative HCV viral load result at 48 weeks of HCV therapy; and sustained virological response, defined as a negative HCV viral load result obtained at least 24 weeks after cessation of HCV therapy [17] [18] [19] . Patients who prematurely withdrew from HCV therapy prior to 48 weeks of treatment were considered not to have had end-of-treatment or sustained virological responses, unless they had a documented negative HCV viral load at least 24 weeks after treatment discontinuation. Diagnostics, Branchburg, NJ, USA: detection limit of <600 IU/ml; Cobas TaqMan, Roche Diagnostics, Pleasanton, CA, USA: detection limit of <10 IU/ml; Versant HCV RNA 3.0 Quantitative Assay, Bayer Diagnostics: detection limit of <615 IU/ml, according to the available technique at each site] and liver biopsy results [if available]) were abstracted from dates closest but prior to the date of HCV treatment initiation. Liver fibrosis staging was assessed via METAVIR score in all patients for whom a liver biopsy had been performed prior to initiating HCV therapy [20] . Advanced fibrosis was defined by the presence of bridging fibrosis or cirrhosis (that is, METAVIR stages 3 or 4). A 10% random chart re-abstraction was performed to validate the accuracy of data collection.
Data collection
PEG-IFN-α2a dosages were categorized as 180 µg/ week or less, whereas PEG-IFN-α2b dosages were categorized as <1.1, 1.2-1.3 or ≥1.4 µg/kg/week to allow for clinician rounding of patient body weight. Ribavirin was categorized as at or above recommended levels: HCV genotypes 1 or 4 (1,000 mg/day for patients ≤75 kg and 1,200 mg/day for patients >75 kg); genotypes 2 or 3 (800 mg/day irrespective of weight) [18, 21] . Patients' progress notes were examined for PEG-IFN and ribavirin dose reductions during therapy. Those who were not prescribed recommended dosages either at baseline or during follow-up were classified as having received suboptimal dosages of these medications.
Statistical analysis
Median declines in log HCV RNA between baseline and week 12 were compared between abacavir users and non-users with Wilcoxon rank-sum tests. Early and sustained virological response was compared between abacavir users and non-users with χ 2 tests. Multivariable logistic regression evaluated the association (odds ratio [OR] ; 95% confidence interval [CI] ) between abacavir use and early virological response, end-of-treatment response and sustained virological response. Potential confounders evaluated included age, sex, race, body mass index, site, HIV/HCV risk factors, baseline CD4 + T-cell count, baseline HIV viral load, degree of liver fibrosis and zidovudine use. We assessed the effect of confounding by examining the change in OR for each comparison as potential confounders were included in the model [22] . Analyses were stratified by HCV genotype. We also performed analyses stratified by site, but results were unchanged (data not shown). Additionally, given the importance of weight-based dosing on virological response, we evaluated outcomes among patients who maintained weight-based PEG-IFN and ribavirin doses throughout their treatment course. We also examined whether use of other antiretrovirals was associated with lack of early or sustained virological response.
Assuming a type 1 error rate of 0.05, a 2:1 ratio of unexposed:exposed, an overall early virological response rate of 55% [23] and that 35% of patients would receive abacavir, a sample size of 180 patients was targeted to provide 80% power to detect a 20% difference in early virological response rate between abacavir users and non-users. All data were analysed using STATA 10.1 (STATA Corp, College Station, TX, USA).
Results
Patient characteristics
A total of 265 coinfected patients were prescribed PEG-IFN plus ribavirin during the observation period. Of these, 51 patients were not prescribed ART at the time HCV treatment was initiated and two had no baseline HCV viral load result ( Figure 1 ). The final sample included 212 patients (74 [35%] received abacavir). Patients prescribed abacavir more commonly were female, African-American and had a history of injection drug use. There were no significant differences in abacavir use with regards to age, ethnicity, body mass index, diabetes mellitus, zidovudine use, HCV genotype, CD4 + T-cell count, HIV viral load and HCV viral load (Table 1) .
Thirteen patients completed 12 weeks of HCV therapy, but were still on treatment at the time of analysis. As such, they were not included in analyses evaluating end-of-treatment or sustained virological responses.
A total of 121 (57%) patients prematurely withdrew from therapy. Figure 1 ).
Medication dosing
A total of 158 patients (75%) were treated with PEG-IFN-α2a, 149 (94%) of whom initiated the recommended dose of 180 µg/week. An additional five patients had their PEG-IFN-α2a dose decreased during follow-up so that overall 14 (9%) received a suboptimal PEG-IFNα2a dose. Fifty-four patients (25%) were treated with PEG-IFN-α2b, 50 (93%) of whom started on at least 1.4 µg/kg/week. The remaining four (7%) started on at least 1.2 µg/kg/week. No patients had PEG-IFN-α2b dose reductions during follow-up. Thus, a total of 18 patients received suboptimal PEG-IFN dosages during their HCV treatment.
Among patients with genotypes 1 or 4, 63 (34%) were prescribed a reduced ribavirin dosage. An additional five patients had their ribavirin dose decreased during follow-up so that overall 68 (37%) received a suboptimal ribavirin dosage. All patients with genotypes 2 or 3 started and remained on at least 800 mg of ribavirin.
HCV viral load declines at 12 weeks
Overall, the median decline in HCV viral load at 12 weeks was similar for patients prescribed abacavir compared with those not receiving this medication (1.15 versus 1.94 log IU/ml; P=0.5). Among patients with HCV genotypes 1 or 4, median viral load declines at 12 weeks were similar between abacavir users and non-users (0.93 versus 1.50 log IU/ml; P=0.8). For patients with HCV genotypes 2 or 3, median viral load declines were smaller for those who received abacavir (3.60 versus 5.93 log IU/ml; P=0.06).
When a subanalysis was performed excluding the 68 patients who received suboptimal ribavirin doses during the initial 12 weeks of HCV therapy, viral load declines were not statistically different by abacavir use (1.80 versus 2.30 log IU/ml; P=0.7). Among patients with genotypes 1 or 4 who received optimal ribavirin doses over the initial 12 weeks, median declines in HCV viral load at 12 weeks were similar among abacavir users and non-users (1.15 versus 1.56 log IU/ml; P=0.6). + T-cell count and baseline HCV viral load, abacavir use was not associated with a reduced risk of early virological response overall (adjusted OR 0.99; 95% CI 0.53-1.84) or for genotype 1 or 4 patients (adjusted OR 1.00; 95% CI 0.50-2.00). Sample sizes for genotypes 2 or 3 were insufficient for multivariable analyses. In subanalyses performed among patients who maintained optimal ribavirin dosages, abacavir remained unassociated with a reduced risk of early virological response (Table 2) .
Early virological response
End-of-treatment response
Fifty-eight (27%) patients had an end-of-treatment response (14 [19%] load, there remained no significant association between abacavir use and end-of-treatment response among genotype 1 or 4 infected patients (adjusted OR 1.08; 95% CI 0.41-2.55). Sample sizes for genotypes 2 or 3 were insufficient for multivariable analyses. 
Sustained virological response
Other antiretroviral agents and virological response
The nucleoside analogues zidovudine, tenofovir, lamivudine and emtricitabine were not associated with reduced 12-week HCV viral load declines, lack of early virological response or lack of sustained virological response (Table 4) . Use of non-nucleoside reverse transcriptase inhibitor or protease inhibitor antiretroviral classes was also not associated with these outcomes.
Discussion
In this study, use of abacavir was not associated with reduced early or sustained virological response either overall or by HCV genotype. Among genotype 1 and 4 infected patients, median declines in HCV viral load over the initial 12 weeks of PEG-IFN plus ribavirin therapy were similar between abacavir users and non-users. In addition, in analyses performed among patients prescribed weight-based ribavirin dosages, no differences were observed in median HCV viral load declines at 12 weeks between abacavir users and non-users. In contrast, median declines in HCV viral load at 12 weeks for genotype 2 and 3 patients, all of whom received 800 mg/ day of ribavirin, were substantially smaller among patients on abacavir, although there were no significant differences in early or sustained virological response. Furthermore, no other antiretroviral medications were associated with lack of virological response.
Our results are consistent with a previous cohort study of 244 coinfected patients treated with PEG-IFN plus ribavirin at four hospitals in Spain (85% on ART; 49 [24%] on abacavir; 97% prescribed ≥13.2 mg/kg/ day of ribavirin), which reported that patients receiving abacavir in the setting of weight-based ribavirin achieved similar sustained virological response rates compared with non-users (46.2% versus 46.7%; OR 1.03; 95% CI 0.55-1.94) [12] . The results of these studies suggest that the putative competitive effect between abacavir and ribavirin can be overcome with optimal weight-based ribavirin dosages.
Our findings differed from several other studies examining the association between abacavir use and HCV virological response. A retrospective analysis of 154 coinfected patients (22 receiving abacavir) enrolled in the French National Agency for Research on AIDS and Viral Hepatitis (ANRS) HC02-Ribavic trial reported that abacavir use was an independent predictor of early virological failure to combination HCV therapy (adjusted OR 4.9; 95% CI 1.5-16.1) [11] . However, all patients in this trial received 800 mg/day of ribavirin. In addition, a retrospective cohort study of 493 coinfected patients (78% on ART; 115 receiving abacavir) prescribed PEG-IFN plus ribavirin Table 2 . Early virological response rates according to use of abacavir, by genotype and among patients receiving optimal dosages of PEG-IFN and ribavirin a Odds ratios were adjusted for age, sex, race, fibrosis stage, methadone use, zidovudine use, baseline CD4 + T-cell count and baseline HCV viral load. P=0.03). Differences in ribavirin dosing and the study populations, which were exclusively European, might account for the disparate results between studies. Additionally, some studies were not restricted to patients only receiving ART, which makes those results subject to confounding by indication [24] . We observed that the initial 12 week HCV viral load decline in patients infected with HCV genotypes 2 or 3 was substantially smaller among abacavir users. As these patients were all prescribed non-weight-based ribavirin dosages (that is, 800 mg/day), it is possible that abacavir might interfere with ribavirin's activity at these lower ribavirin dosages. The relatively small number of patients with genotypes 2 or 3 in this study limits our ability to draw definitive conclusions. Additional studies in coinfected patients with genotype 2 or 3 should be performed to examine if the use of weightbased dosages of ribavirin can increase the viral load decline at 12 weeks.
Our analyses demonstrated that no other antiretroviral medications compromised early or sustained virological responses to HCV therapy. In particular, our findings did not corroborate an earlier study reporting that the use of ritonavir was associated with reduced early and sustained virological response rates [25] . In addition, increases in pre-treatment total bilirubin have been reported to increase the risk of early virological failure (adjusted OR 4.5; 95% CI 1.5-13.4) [11] . As the antiretroviral medication atazanavir can cause hyperbilirubinaemia, use of this medication might reduce the risk of early virological response; however, we found no association between atazanavir and HCV virological non-response. Moreover, no other antiretroviral medication or classes were associated with lack of virological response.
Our study had several limitations. Firstly, the retrospective design of the study did not allow all potential confounders to be collected. Although a number of variables were evaluated and controlled for analytically, multivariable analyses might not entirely eliminate residual confounding from additional unmeasured factors, as is always true for all observational studies. In particular, we did not have information on the duration of HCV infection, because this was not routinely collected in medical records, and were unable to measure adherence to PEG-IFN and ribavirin therapy [10] , as pharmacy refill data were not available at all sites. We therefore could not examine the relationship between these variables and response to HCV therapy.
Secondly, although this study drew patients from six sites, some secondary analyses had small sample sizes. There was also a high overall rate of HCV treatment discontinuation, which contributed to the low sustained virological response rates observed in this study. These factors limited our ability to identify potentially important associations. Our results should be interpreted with caution as early virological response was the primary outcome and the main strength of ribavirin is in the prevention of relapse, which is mainly reflected by rates of sustained virological response. As additional studies of similar design are reported, formal methods of meta-analysis could be used to combine results across studies and perhaps add to the precision of our findings. Thirdly, patients who received abacavir more frequently discontinued HCV therapy prematurely, and the most common reason for withdrawal was virological non-response. This increased rate of HCV treatment discontinuation might have been due to abacavir interfering with the antiviral activity of ribavirin, ultimately resulting in virological non-response and withdrawal from therapy.
Finally, the study only included patients from the US and it might not be possible to generalize these results to coinfected patients in other areas.
In conclusion, our study found that use of abacavir, as well as other antiretrovirals, was not associated with a lack of early or sustained virological response. Additional studies are needed to determine if weightbased dosages of ribavirin can enhance HCV viral load declines among genotype 2 and 3 abacavir users.
